Drug
Foslevcromakalim clinical trials
Also written QLS-101.
- studies test it
- 4
- open now
- 0
- in phase 3
- 0
- first study started
- 2021
How studies write it
Studies that test it under each name
Development codes
Studies by the year they started
4 studies that test it; most in 2021 (3)
| Year | Studies |
|---|---|
| 2021 | 3 |
| 2022 | 1 |
By phase
A phase 1/2 study counts in both.
- Phase 2
- 4
What it is tested for
Each study’s main condition, where its own words name it.
Who runs them
Industry 4 · Other 0
Qlaris Bio, Inc. (4)
Studies
Open first, then newest update. How each study uses foslevcromakalim is read from its arms, and is right about nine times in ten.
Testing it · 4
- A Study to Evaluate Safety and Tolerability of QLS-101 in NTGCompletedPhase 2Qlaris Bio, Inc.NCT04857827Written as QLS-101
- Safety and Tolerability Study of QLS-101 in Adolescents With Sturge-Weber Syndrome (SWS)-Related Glaucoma Due to Elevated Episcleral Venous Pressure (EVP)CompletedPhase 2Qlaris Bio, Inc.NCT05495269Written as QLS-101 ophthalmic solution, 2.0 %
- A Study to Determine the Safety and Tolerability of 2 Concentrations of QLS-101CompletedPhase 2Qlaris Bio, Inc.NCT04947124Written as QLS-101ophthalmic solution 1%
- Study to Evaluate QLS-101 Compared to Timolol Maleate Eye Drops in Subjects With High Eye Pressure (Glaucoma or Ocular Hypertension).CompletedPhase 2Qlaris Bio, Inc.NCT04830397Written as QLS-101
Codes
What other systems call foslevcromakalim · ClinicalTrials.gg INT014732
- UNII (FDA) 3U3LYD9HK6FOSLEVCROMAKALIMOne source FDA
- NCI Thesaurus C190143FoslevcromakalimOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| UNII (FDA) | 3U3LYD9HK6 | FOSLEVCROMAKALIM | One source FDA |
| NCI Thesaurus | C190143 | Foslevcromakalim | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.